Defo E.T.a,b, Tsapi A.T.b,c, Fossi M.d, Dongho B.D.b,c, Nguefack-Tsague G.e, Zogning E.M.f,b, D.F. Achug, Ekobe G.E. g, Russo G.c, Ethgen O.a. Sobze M.S.h*.

aDepartment of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium.
bFaculty of Sciences and Technology, Evangelical University of Cameroon, Bandjoun, Cameroon.
cDepartment of Infectious Diseases, Microbiology and Public Health; University of Rome “La Sapienza”, Rome, Italy. dDepartment of Medicine, University of Liege, Liege, Belgium
eDepartment of Public Heath, Faculty of Medicine and biomedical sciences, University of Yaoundé I, Cameroon fDepartment of Experimental Medicine and surgery, “Tor Vergata” University of Rome, Rome, Italy
gNational Malaria Control Program (NMCP), Ministry of Public Health, Cameroon.
hFaculty of Medicine and Pharmaceutical Sciences, University of Dschang, Dschang, Cameroon.


Objectives: The purpose of this study was to determine the average price that a patient living in Cameroon would be willing to pay for the MosquirixTM vaccine and the factors influencing the proposed price.

Study design: Cross-sectional study

Methods: Data were collected using a semi-open questionnaire in 5 hospitals in Cameroon. This study included all persons over 18 years who came for consultation in one of the 5 selected hospitals during the study period (from 02th to 14th April 2018 and from 02th to 22th July 2018). The factors associated with the price of the vaccine proposed by the patient were determined by linear multiple regression analysis. The average price was determined based on the patient’s income and the percentage of that income proposed for the purchase of the vaccine.

Results: We collected data from 1,187 participants aged 18 to 80 years. The average price that Cameroonian patients were willing to pay for the MosquirixTM vaccine was 1,514±475 XAF (2.3±0.73 Euro). The minimum and maximum purchase price of the vaccine were 1,178 XAF (1.8 Euro) and 1,850 XAF (2.8 Euro) respectively. We also noted that patients were willing to spend an average of 1.34% of their income on the vaccine.

This percentage of income was significantly (p<0.001) associated with the respondents’ income, the fact that they had been consulted at least once for malaria in the 12 months preceding the survey (p<0.001) and the fact that the respondent had at least one under- five year child (p<0.001).

Conclusion: Factors associated with the average price are elements that should be strongly considered by policy makers to introduce this vaccine in Cameroon. This pilot study can serve as a framework for a potential national population-based study.

Download PDF